IJPSN Award to Dr.MS Reddy for a Breakthrough Adjunct Cancer Therapy

Indian-American Scientist Dr. M.S. Reddy (Dr. Malireddy Srinivasulu Reddy) has been honored with the 2018 IJPSN Award for his breakthrough research on adjunct cancer therapy published in the International Journal of Pharmaceutical Sciences and Nanotechnology (IJPSN). The editor’s team has conferred this top honor for his outstanding scientific paper on Multiple Mixed Strain Probiotic Adjuvant Cancer Therapy. This serendipitous discovery has the potential to effectively treat cancer and save millions of people worldwide positive manipulation of the gut microbiome.

Cancer affects about 18.1 million worldwide with 9.6 million deaths in 2018 alone.  This means, every sixth death in the world is due to cancer.  Earlier, Dr. Reedy has discovered a Multiple Mixed Strain Probiotic Therapy to prevent the hospital acquired infections due to multiple antibiotic resistant superbugs, such as MRSA and C. diff.  While conducting the community clinical trial with Probiotics fore hospital acquired infections, he came up with a serendipitous discovery to cure cancer with a significantly greater efficiency using Multiple Mixed Strain Probiotic Therapy in combination with standard cancer therapies. This was referred as “Dr. M.S. Reddy’s Multiple Mixed Strain Probiotic Adjuvant Cancer Therapy”. It is thought to establish immune tolerance and thus helps the primary cancer therapy to be most effective, with least or no side effects.  It also significantly reduces the relapse of cancer, which was proven through community based clinical trials. This was actually accomplished through positive maintenance of the cancer patients gut microbiome, thus establishing the proper immunomodulation, which results in significant reduction of immune stimulation and inflammation. It establishes a positive immune tolerance, which is the prime requisite to synergistically improve the efficiency of the standard cancer therapies.

The Probiotic Adjuvant Cancer Therapy is the best complementary therapy for cancer along with the use of immune checkpoint therapy and other standard-of-care therapies. Ultimately, this could be the answer to prevent or treat cancer with over 80% accuracy with no immune related side effects and with least relapse. Thus, cancer can be treated using such a complementary therapy as a choice therapy than a chance therapy, to save lives of people with cancer and also to prevent cancer. This for the first time has provided a missing link in the successful treatment of cancer from Dr. Reddy’s work.

Dr. Reddy is the President of ADFAC Labs, Inc. and IMAC, Inc. located at Denver, Colorado, U.S.A.  He has received bachelor of veterinary science (DVM), and M.S. and Ph.D. degrees from Iowa State University, USA, in food technology, microbiology, and bacteriology.  He has been working on Probiotics throughout his life, and has published over 130 research articles and has over 150 national and international patents.  He has received over 165 honors and awards from all over the world for his scientific contributions at world level, mainly pertaining to the beneficial human health improving micro-organisms.  Among the notable are Richard Hoyt Memorial Award from the American Dairy Science Association and National Milk Producers Federation of Washington D.C., President Ronald Regan Gold Medal Award, Outstanding Young Alumnus Recognition Award from Iowa State University,  Outstanding Scientist Award from IAFC of Washington, DC, Best Medical Science Award in 2016 for his discovery to cure or prevent hospital acquired or nosocomial infections, Best Researcher Award for his discovery on enhancing drug efficiencies through introduction of Probiotics along with the pharmaceutical drugs, and several Lifetime Achievement Awards in Science & Technology from many American and international organizations.